Corvus Pharmaceuticals (CRVS) Cash from Operations Growth (3y) (2018 - 2026)

Corvus Pharmaceuticals (CRVS) Cash from Operations Growth (3y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Corvus Pharmaceuticals 1.23 Bn 1.23 Bn - -8.55%

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.55%
Dec 31, 2025 -6.79%
Sep 30, 2025 -11.35%
Jun 30, 2025 1.92%
Mar 31, 2025 -8.75%
Dec 31, 2024 -7.36%
Sep 30, 2024 9.13%
Jun 30, 2024 24.32%
Mar 31, 2024 16.28%
Dec 31, 2023 14.29%
Sep 30, 2023 11.09%
Jun 30, 2023 18.04%
Mar 31, 2023 4.64%
Dec 31, 2022 3.92%
Sep 30, 2022 13.23%
Jun 30, 2022 12.74%
Mar 31, 2022 10.60%
Dec 31, 2021 6.08%
Sep 30, 2021 7.94%
Jun 30, 2021 -5.12%